Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALSENLITE: Dasatinib and Quercetin in Alzheimer's Disease
NCT04785300Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Mayo Clinic. Started Jul 2022; status: active, not recruiting.
02
Drugs
dasatinibquercetin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04785300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785300.